MBP-134 AF

N/A

Report date: 2025/06/11 10:29:50

Base Information

Drug NameMBP-134 AF
Drug Alias Nameneutralizing mAbs (Albert Einstein College of Medicine/Adimab/Mapp Biopharmaceutical)neutralizing mAbs (Albert Einstein College of Medicine)neutralizing anti-ebola virus antibodies (Adimab)ADI-15878ADI-15742
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsMarburg Virus DiseaseHemorrhagic Fever, Ebola
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAlbert Einstein College Of Medicine Inc
China Registration ClassN/A

Develop Information

Active CompaniesMapp Biopharmaceutical IncAdimab LLCAlbert Einstein College Of Medicine Inc
Inactive CompaniesN/A
Active IndicationsMarburg Virus DiseaseHemorrhagic Fever, Ebola
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A